The multi-year collaboration leverages Docquity's Awareness to Advocacy (A2A) Program to expand retinal health education amongst thousands of HCPs and widen access to retinal health products With 81.5 ...
Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory ...
AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...
The Department of Health and Human Services (HHS) has filed for summary judgment in its favor regarding lawsuits brought by ...
Novartis shareholders elected Giovanni Caforio as new member and Chair of the Board of Directors as well as Elizabeth McNally as new member of the Board of Directors. Joerg Reinhardt, Charles L.
Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing ...
Novartis is paying Kyorin $55 million upfront for exclusive global rights to develop, manufacture and commercialize KRP-M223, a preclinical mast-cell-targeting candidate for chronic spontaneous ...
Novartis is spending $55 million on global rights to Kyorin Pharmaceutical’s preclinical drug for inflammatory diseases in a deal that comes almost two ...
Translink has confirmed that Metro 9 services will be returning to their original location in Belfast opposite the City Hall in Donegall Square East. Passengers getting those services previously ...
Sumeet, Global Head of Service Enablement & Governance, People Services & Solutions Few companies in India offer this kind of benefit to their people, but I am fortunate to be working with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback